Exact Sciences Corp (NASDAQ: EXAS) has experienced a decline in its stock price by -0.63 compared to its previous closing price of 60.75. However, the company has seen a fall of -1.96% in its stock price over the last five trading days. globenewswire.com reported 2024-12-09 that ALEXANDRIA, Va., Dec. 09, 2024 (GLOBE NEWSWIRE) — The American Academy of Physician Associates (AAPA) is proud to announce a new project, made possible through a grant from Exact Sciences, that aims to improve colorectal cancer screening rates.Physician associates/physician assistants (PAs) are often one of the first healthcare providers a patient sees, and thus are uniquely positioned to discuss screenings early on with patients.AAPA Chief Medical Officer Jennifer M. Orozco-Kolb, DMSc, PA-C, DFAAPA, said PAs play an important role in educating and encouraging patients to complete colorectal cancer screenings.“The 5-year survival rate for a patient who is diagnosed with colorectal cancer in the early stages is upward of 91%,” Orozco-Kolb said. “When a patient is diagnosed at a later stage, that survival rate drops to almost 14%. Screening through either at home DNA stool testing or traditional colonoscopy procedures should be considered when having conversations with patients about what works best for them.”The project consists of three phases. The first phase, which is underway, will feature focus group meetings with four federally qualified health centers (FQHCs) in Wisconsin and Arizona that previously received Exact Sciences funding to complete projects that improved colorectal cancer screening rates. These FQHCs were selected because they often serve underserved or uninsured patients who are less likely to access and complete colorectal cancer screenings.These focus group meetings are expected to be completed by February 2025, when the second phase of the project will begin. This phase involves taking lessons learned and best practices gathered during the focus groups and creating an innovative toolkit that can be widely used by providers across the country to improve their own colorectal cancer screening rates.The third phase will consist of taking the newly developed toolkit and implementing changes at select clinics across the country to measure outcomes.In 2024, the American Cancer Society ranked colorectal cancer as the third deadliest form of cancer in men, and fourth deadliest cancer in women. It’s estimated that more than 152,000 people nationwide will be diagnosed with colorectal cancer this year.### Media Contacts: AAPA: Josh Birch, 443.614.5896 About the American Academy of Physician Associates (AAPA) AAPA is the national membership organization for all physician associates/physician assistants (PAs). PAs are licensed clinicians who practice medicine in every specialty and setting. Trusted, rigorously educated and trained healthcare professionals, PAs are dedicated to expanding access to care and transforming health and wellness through patient-centered, team-based medical practice. Learn more about the profession at aapa.org and engage through Facebook, LinkedIn, Instagram, and Twitter.
Is It Worth Investing in Exact Sciences Corp (NASDAQ: EXAS) Right Now?
Additionally, the 36-month beta value for EXAS is 1.23. There are mixed opinions on the stock, with 17 analysts rating it as a “buy,” 3 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EXAS is 182.38M and currently, short sellers hold a 6.49% ratio of that float. The average trading volume of EXAS on December 18, 2024 was 2.47M shares.
EXAS’s Market Performance
The stock of Exact Sciences Corp (EXAS) has seen a -1.96% decrease in the past week, with a 22.38% rise in the past month, and a -12.77% fall in the past quarter. The volatility ratio for the week is 3.39%, and the volatility levels for the past 30 days are at 4.01% for EXAS. The simple moving average for the last 20 days is 1.08% for EXAS’s stock, with a simple moving average of 3.63% for the last 200 days.
Analysts’ Opinion of EXAS
Many brokerage firms have already submitted their reports for EXAS stocks, with Wells Fargo repeating the rating for EXAS by listing it as a “Overweight.” The predicted price for EXAS in the upcoming period, according to Wells Fargo is $75 based on the research report published on August 28, 2024 of the current year 2024.
Scotiabank, on the other hand, stated in their research note that they expect to see EXAS reach a price target of $70. The rating they have provided for EXAS stocks is “Sector Outperform” according to the report published on June 27th, 2024.
Jefferies gave a rating of “Buy” to EXAS, setting the target price at $75 in the report published on June 03rd of the current year.
EXAS Trading at -3.45% from the 50-Day Moving Average
After a stumble in the market that brought EXAS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.18% of loss for the given period.
Volatility was left at 4.01%, however, over the last 30 days, the volatility rate increased by 3.39%, as shares surge +21.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.82% lower at present.
During the last 5 trading sessions, EXAS fell by -1.96%, which changed the moving average for the period of 200-days by +1.98% in comparison to the 20-day moving average, which settled at $59.72. In addition, Exact Sciences Corp saw -18.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EXAS starting from Conroy Kevin T, who purchase 19,500 shares at the price of $51.35 back on Nov 13 ’24. After this action, Conroy Kevin T now owns 1,074,191 shares of Exact Sciences Corp, valued at $1,001,325 using the latest closing price.
Baranick Brian, the EVP, GM, Precision Oncology of Exact Sciences Corp, sale 929 shares at $70.00 during a trade that took place back on Oct 08 ’24, which means that Baranick Brian is holding 12,758 shares at $65,030 based on the most recent closing price.
Stock Fundamentals for EXAS
Current profitability levels for the company are sitting at:
- -0.09 for the present operating margin
- 0.72 for the gross margin
The net margin for Exact Sciences Corp stands at -0.08. The total capital return value is set at -0.04. Equity return is now at value -6.76, with -3.25 for asset returns.
Based on Exact Sciences Corp (EXAS), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at 0.09. The debt to equity ratio resting at 0.8. The interest coverage ratio of the stock is -10.02.
Currently, EBITDA for the company is 41.88 million with net debt to EBITDA at 82.57. When we switch over and look at the enterprise to sales, we see a ratio of 4.96. The receivables turnover for the company is 10.17for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.12.
Conclusion
In conclusion, Exact Sciences Corp (EXAS) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
